2014年9月28日 星期日

心酸- 跟賭徒一樣的中華隊

這幾年國際棒球的中華隊, 都有幾個共通點,

1.  一定會輸在七八局!
2. 在沒人出局得分門口未得分的後一局, 一定穩爆!
通常都是一次就死個4分以上, 反正丟分後壘上跑者一定要清光,
然後才會有默默無名的台灣土砲上來穩穩的把後面的局數吃掉!

我覺得, 就是那種藏在骨子裡的那種民族自卑感與賭徒性格, 以及過度舒適環境帶來那種極低的抗壓性!

稍稍解釋一下:

民族自卑感:

1. 當然是旅外的好, 去喝過洋墨水的回來一定比較厲害!台灣草創20多年的職棒培養出來的選手怎麼會比出去美國回來的好??!!無論是手臂爛掉, 狀況好壞,一定比本國的好!!
(本次亞運, 被扣倒的那場比賽, 大家賽後罵得就是這一點,今天還是一樣!)

賭徒個性:

1. 跟上面的類似!即使旅外投手狀況再差,一定比台灣的選手好!我們賭賭看,或許他今天就回穩了也說不定!
2. 在選投手時,是不是有考慮到兩個等強的後援投手?或是那種穩定但沒人見過得投手?感覺投手戰略還是20年前的"勝利方程式"式一條鞭的樣子!七局換投我就知道一定是羅嘉仁要上來!那韓國隊教練一定也知道。或許當時韓國教練就已經" 嘿嘿嘿!贏定了!"
3. 選教練的時候, 只要以前是好球員就是好教練!有沒有受過足夠教練訓練的都不重要!!

(其實我真的很期待10年後看到張泰山+王建民+陳韋殷+陳金鋒的組合!而且應該不遠了!)

4. 每賭必輸!輸到會怕卻又愛賭!反正已經有銀牌了,獎金也拿到,下一屆也不是我了!賭一下我損失不大,被罵又不會痛,拼了拉!!

極低的抗壓性:
這個不用我講了,你以為每個人都是高志剛喔....囧

你以為只有球員教練是這樣嗎?
那各位球迷們,
為什麼每次都知道一樣的結果,卻每次都杵在電視機前面當另一個笨蛋賭徒呢?

更可悲的是,我們只能當鍵盤教練與球評,然後,世界依然運轉,中華隊仍然繼續爛下去,我們還是贏不了韓國,中華職棒仍然繼續草創!而我們仍然抱持著一絲希望,迎接永無止境的失望!!

這已經不是一句" 加油好嗎?" 可以形容的了.... Sad...

2014/09/28 仁川亞運, 還是輸給韓國隊之後..

我們的世界, 正在加速.. 好友聚會後有感

好久不見的朋友,聊著不同職業中對相同時代的不同看法,與各自的解決之道...

理無對錯,互相討論總有收穫!光正一語深得我心:
"十年前的領導書籍教我們的東西,十年後好像都變了!"

是阿,十年前,我們還在上b聊天,email 剛開始,paper只要10年內都還有效的年代的我們,怎麼會想到現在已經到五年,甚至3年前的資料都已經過時的年代⋯

而我們,面對這麼大規模的資料,所具備的搜索技巧,卻仍與10年前無異⋯

晚上,看了文茜,提到一點:當菲律賓的工程師跟你的你能力一樣,但價錢是你的三分之一,是誰會沒工作⋯

是阿!如果只守著老師給的觀念,幻想著仍有一片榮景,追逐著傳統方法所帶來的微薄利益,是否十年後,我們將會是第一批失業的醫護人員?

1960年代,手機還只是電影內的想像,2030年代,或許半數以上的醫療護理工作,都將由全能醫療艙取代!誰說醫師一定不會失業?!

我們的資源的確比不上老師們,但,"above our anger",如陳文茜所說,我們應該要有更好的能力,更多的想法,不停的突破,才能在這個"失落的年代",活出不失落的自我!

給朋友們,共勉之!

2013/09/27 台南 彤玥工作室小聚 後

2014年8月3日 星期日

老網址, 找了好久的備份
還是年少輕狂的記憶阿!!

http://blog.xuite.net/jamihan1981911/wretch

2013年5月11日 星期六

20130512 移植相關 issue

Ann of Surg- PAP

A Retrospective Study on Risk Factors Associated With Failed Endoscopic Treatment of Biliary Anastomotic Stricture After Right-Lobe Living Donor Liver Transplantation With Duct-to-Duct Anastomosis

A retrospective study was performed on 287 patients who received right-lobe living donor liver transplantation with duct-to-duct anastomosis. 

The morphology of BAS was categorized into 3 types: pouched, intermediately pouched, and triangular. 

Results: 

Fifty-nine patients (20.6%) had BAS and received ERC and balloon dilatation with or without stenting. 

The success rate was 73.2%. 

The median number of sessions needed for successful ERC was 3. 

In the 15 patients with failed ERC,
4 : percutaneous transhepatic biliary drainage and balloon dilatation, 11: hepaticojejunostomy 

Risk factors for failed ERC:
Recipient age [odds ratio (OR): 0.922; 95% confidence interval (CI): 0.85-1.00; P = 0.049], Operation time (OR: 1.007; 95% CI: 1.001-1.013; P = 0.025),
Morphology of stricture (OR: 6.722; 95% CI: 1.31-34.48; P = 0.022)

The success rates for the 3 types of BAS-pouched, intermediately pouched, and triangular-were 42.9%, 63.6%, and 88.9%, respectively (P = 0.021). Association was found between bile leak and pouched BAS (P = 0.008).

Transplantation 15 May 2013 - Volume 95 - Issue 9

Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review

Six randomized controlled trials (n=2499) and 15 observational studies (n=2886) were included in the review. 

Results:

No significant differences in
biopsy-proven acute rejection (two trials, n=1093; risk ratio [RR; confidence interval (CI)], 1.24 [0.93–1.65]; P=0.15; I2=0%),
patient survival
(three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.55; I2=32%), and
graft survival
(three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.67; I2=0%) between the two formulations at 12 months. 

Similar results for
acute rejection
(five studies, n=391; RR [CI], 0.99 [0.93–1.06]; P=0.84; I2=0%) and
overall patient survival
(two studies, n=218; RR [CI], 1.02 [0.94–1.10]; P=0.62; I2=0%) were observed in observational studies. 

Conclusions: Once-daily tacrolimus appears to be as effective as twice-daily tacrolimus up to 12 months after kidney transplantation.

De Novo Malignancies After Adult-to-Adult Living-Donor Liver Transplantation With a Malignancy Surveillance Program: Comparison With a Japanese Population-Based Study

360 adult LDLT recipients who survived more than 1 year after transplantation. 

Results: Mean follow-up period was 7.5±3.4 years.
During the follow-up period, 27 de novo malignancies were diagnosed in 26 recipients. Colorectal cancer was the most commonly detected malignancy. 

The overall mortality of the recipients with de novo malignancies was similar to the findings of the Japanese general population-based study (standardized mortality ratio=0.9). 

Overall, the incidence of cancer was significantly higher in transplant recipients than in the Japanese general population (standardized incidence ratio=1.8). 

The 5-year estimated survival rate of recipients with de novo malignancies was 81% and those of recipients without malignancies was 93% (P<0 .0001="" font="" nbsp="">

Conclusions: Colorectal malignancies predominated in Japanese liver transplant recipients. Although de novo malignancies correlated with a poor prognosis, the standardized mortality ratio was 0.9 compared with that of subjects of a Japanese population-based study.

2013年4月7日 星期日

Hepatic Hydrothorax and Treatment

Cause: 因為已經被問到兩次了,而且有人說可以把Diaphragm補起來...所以來查查!! 

Definition: recurrent pleural effusion in patients with end-stage liver disease and portal hypertension in the absence of comorbid cardiac or pulmonary disease

Theories:
1955: hydrothorax develop frequently have defects in the diaphragm that permit egress of ascites into the negative-pressure space of the pleural cavity 
=> Intra-abdominal pressure elevated -> Diaphragm herniation -> rupture to pleural space
=> Can be seen under following the passage of various tracers—air, dyes, and radiolabeled substances—from the peritoneal to pleural compartments and by direct thorascopic visualization of the defects (1992~2005)

2007: Development of hydrothorax include transdiaphragmatic leakage of fluid from lymphatic channels and azygos vein hypertension 

Icidence: 5~12%
More right side(85%), 仍有Left side(13%) or bilateral side(2%)!!

Diagnosis:
Thoracocentesis: transudative by traditional criteria of Light and colleagues
(From Aliment Pharmacol Ther 2004; 20: 271–279.)


Treatment:
For relieve dyspnea 
=> Therapeutic thoracentesis , 
=> No need of chest tube:
      induced infection, acute renal failure, 
and reflecting large volume loss , even poor outcomes

Medical Management: Similar to ascites 
          => diet salt restriction(low sodium diet of 70–90 mmol/day) and 
               diuretics(BEST: furosemide 40 mg/day and spironolactone 100 mg/day.)
                              => Doubling dose 3-5 days, 
                              => up to spironolactone up to 400 mg/day and furosemide up to 160 mg/day.
          => Early TIPS -> But not so sure as ascites-> 79% and 75 % response at POM1 and POM6 
                (Dhanasekaran et al, 2009). 
                      但如果不能作TIPS, 那就不好處理了~~~

(From Aliment Pharmacol Ther 2004; 20: 271–279.)
Surgical treatment:
Definite: Liver transplantation!!
Other surgical tx: 

# Timing: TIPS or VATS  repair of the diaphragmatic defects (with or without pleurodesis) are effective strategies in those who are not transplant candidates or those awaiting organ availability.
(from Ann Hepatol. 2008 Oct-Dec;7(4):313-20.)

=> Surgical repair of the diaphragmatic defects => 問題還是Child C 的Morbidity and Mortality!

=> Traditional thoracoscope + talc
     Chest 2000; 118: 13–7.
     thoracentesis followed by talc poudrage under thoracoscopy        and repair of diaphragmatic defects if seen
     18 patients with 21 procedures
     => Diaphragm defect was only in 5 pts. (27.8%)
     => High morbidity (57.1%) and mortality (38.9%)
     => Only 10/21 (47.6%) effective
     => 43.7% recurred and with complication 
     
=> VATS + talc Pleurodesis + repair
      Chest. 1996 Apr;109(4):1093-6.
     8 patients underwent VATS to localize and close of diaphragmatic defects!
     2 no defects, Drainage placed for 15 and 18 days, Volume: 3 and 4L
     6 with defects(75%), Drainage placement for 7.6 +/- 1.75 days, Volume:  0.408 +/- 0.157 mL
               No of these 6 pts got recurrence....

      Am J Gastroenterol 2002; 97: 3172–5.
        15 pts with VATS + talc pleurodesis
      11/15 (73%) resolution at 1st month, 
          8/11: asymptomatic after median 5.5 m/o f/u
          3/11:recurr between 45~60 days after VATS
     Complications: Pain, Low grade fever, fistula and empyema!

=> VATS + talc Pleurodesis , no repair
      Ann Thorac Surg. 2003 Mar;75(3):986-9. 
     => Conclusion: Even with tunnel, Talc pleurodesis still effect! 
                               -> In poor clinical status, repeat injection may be useful!
                            VATS+pleurodesis: a choice!
      13 pts underwent VATS + Pleuraodesis, 
          => 2 of them with defects(15.4%), 1 of them with fluid leakage
          => 10 of them no recurrence, 2 of them got late recurr before dying from cirrhosis
                1 of them ear;y recurrence -> following Talc pleurodesis 
      8 pt cannot tolerate GA-> Chest tube insertion
          => 3: Septic shock-> die! 
          => 3: early recurrence -> Cured after Talc pleurodesis
               1: mid-term
               1: early recurr -> Tx with TIPS -> Partial improvement!! 
      Ann Thorac Surg. 2006 Aug;82(2):457-9. 
     => VATSsurgery with talc is safe and successful in about 3/4 of patients, 
           but repeat talc slurry through the chest tube or repeat VATS is often needed.
     => An alternative effective Tx to TIPS
     41 pts underwent VATS + talc pleurodesis, followed 6 m/o
     => Only 2 patient with defect (<5 font="">
     => 1/40 (2.5%) Mortality -> Intra-operative, Due to coagulopathy!
     => 7/41 (17%) need repeat beside talc injection
     => Overall success rate: 80% (33 / 41)
     => 4 experienced symptomatic fluid collection, and Tx by repeat VATS -> 2/4 success!!

=> VATS + other pleurodesis
     Surg Endosc. 2004 Jan;18(1):140-3. Epub 2003 Nov 21.
     9 pts with VATS ->argon plasma ->   bioabsorbable prostheses
                    -> 3ml fibrin glue and sprinkled 5 KE of OK-432 + 100mg minocyclin
     All clinical improvement, 7/9 successful (77.8%), 
     2 recur at POM1 and POM4, 1/2: success after repet pleurodesis!!

=> Tunnel pleral catheters!!
=> Catheter placement -> as useful in palliative care...

Take home message:
1. 遇到Hepatic Hydrothorax 的病人, 重點還是在Ascites control!!
2. Definite Defect 其實不常見( <5 b="">
3. 治療, 能換肝就換肝, 不能換肝或等換肝太嚴重的, TIPS可以是選擇
   VATS +/- pleurodesis +/- defect repair 也是有效的 (recently可到70~80% 成功率!)
   => This is CS field 
4. 重點還是在這種病人能不能忍受General anethesia, 千萬不要輕易開進去!!!

Reference:
Blumgart’s Surgery of the Liver, Biliary Tract, and Pancreas, 5th edition
Aliment Pharmacol Ther. 2004 Aug 1;20(3):271-9. 
Ann Thorac Surg. 2006 Aug;82(2):457-9. 
Ann Thorac Surg. 2003 Mar;75(3):986-9. 
Chest. 1996 Apr;109(4):1093-6.
Ann Hepatol. 2008 Oct-Dec;7(4):313-20.